Founded in 2011, Innaxon Biosciences is a global leader in Toll-Like Receptor 4 (TLR4) research and innovation. Specialising in Lipopolysaccharides (LPS) with exclusive TLR4-dependent activity, as well as non-TLR4 endotoxin-free ligands, buffers, and immunoceuticals, providing researchers with high-quality tools to advance immune modulation studies.
Innaxon Biosciences provide a diverse product range:
- LPS (Lipopolysaccharides)
- Lipid A
- MPLA (Monophosphoryl Lipid A)
- TLR4/CD14 Inhibitors
- TLR4 MAbs (Monoclonal Antibodies)
- IAXO
- Immunoceuticals
- Lipodisq nano-formulations (SMALP)®
